FIELD: medicine.
SUBSTANCE: multiphase pharmaceutical preparation for ovulation inhibition in mammal contains a number of individually packed and individually removed daily units placed in a single package, and used for oral administration for at least 21 days running; specified daily units contain a combination of oestradiol and drospirenone. A daily unit contains 0.5 to 4 mg of oestradiol and 2 to 4 mg of drospirenone. At least 70% of specified drospirenone are released from specified unit within 30 minutes.
EFFECT: invention provides higher oral bioavailability of drospirenone.
6 cl, 5 dwg, 5 ex
Authors
Dates
2010-08-10—Published
2005-10-14—Filed